As of September 28, 2025, HTG Molecular Diagnostics Inc (HTGM) reports a ROE (Return on Equity) of -400.51%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of HTG Molecular Diagnostics Inc's ROE (Return on Equity)
Over recent years, HTG Molecular Diagnostics Inc's ROE (Return on Equity) has shown significant volatility. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2022-12-31 | -400.51% |
| 2021-12-31 | -164.86% |
| 2020-12-31 | -144.13% |
| 2019-12-31 | -80.52% |
| 2018-12-31 | -78.00% |
This gradual decrease highlights how HTG Molecular Diagnostics Inc manages its efficiency in generating profits from shareholders' equity over time.
Comparing HTG Molecular Diagnostics Inc's ROE (Return on Equity) to Peers
To better understand HTG Molecular Diagnostics Inc's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| HTG Molecular Diagnostics Inc (HTGM) | -400.51% |
| Cytta Corp (CYCA) | 1795.99% |
| NewCardio Inc (NWCI) | 363.85% |
| Ortivus AB (ORTI B.ST) | 347.56% |
| Parallax Health Sciences Inc (PRLX) | 125.47% |
| DATATRAK International Inc (DTRK) | 80.21% |
Compared to its competitors, HTG Molecular Diagnostics Inc's ROE (Return on Equity) is among the lowest compared to peers, which may indicate less effective deployment of shareholders' capital.